0 Itens
  1. You are here:
  2. Proteínas e Enzimas Restrição/Modificadoras
  3. Proteínas
  4. Proteínas Recombinantes
  5. Antígenos Virais e Microbiais
  6. SARS
  7. SARS-ACSMS(M) (residues 408-470/540-573)

SARS-ACSMS(M) (residues 408-470/540-573)

SARS-Associated Coronavirus Spike Mosaic S(M)

recombinant, E. coli

Datasheet (PDF)
Catálogo Nº Apresentação Preço (R$) Comprar / Observação
PR-1106 100 μg Sob demanda Adicionar ao Carrinho

For general laboratory use.

Envio: shipped on gel packs

Condições de armazenamento: store at -20 °C
avoid freeze/thaw cycles

Validade: 12 months

Peso molecular: 38 kDa

Pureza: > 95 % (SDS-PAGE)

Forma: liquid (Supplied in 25 mM Tris-HCl, 0.4% sarcosyl, 0,25% Triton X-100 and 50% glycerol)

Formulários:
Recombinant SARS-ACSM Antigen may be used in ELISA and Western blots, excellent for detection of SARS with minimal specificity problems.

Descrição:
SARS-ACSM contains the middle section of the Spike protein immunodominant fragments, amino acids: 408-470, 540-573. SARS-ACSM is purified by proprietary chromatographic techniques. Background: The spike (S) glycoprotein of coronaviruses mediates viral entry into host cells. Spike (S)-glycoprotein of the virus interacts with a cellular receptor and mediates membrane fusion to allow viral entry into susceptible target cells. It is a type 1 viral fusion protein that characteristically contains two heptad repeat regions, denoted HR-N and HR-C, that form coiled-coil structures within the ectodomain of the protein. Previous studies have shown that the two heptad repeat regions can undergo a conformational change from their native state to a 6-helix bundle (trimer of dimers), which mediates fusion of viral and host cell membranes .

Specificity: Immunoreactive with sera of SARSinfected individuals.

Referências selecionadas:
Xu et al. (2004) Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus. Biochemistry 43:14064. Hsu et al. (2004) Immunological, structural, and preliminary Xray diffraction characterizations of the fusion core of the SARScoronavirus spike protein. Biochem. Biophys. Res. Commun. 324:761. He et al. (2004) Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J. Immunol. 173:4050. Bukreyev et al. (2004) Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 363:2122. Hua et al. (2004) Identification of two antigenic epitopes on SARS-CoV spike protein. Biochem. Biophys. Res. Commun. 319:929. Bosch et al. (2004) Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc. Natl. Acad. Sci. USA. 101:8455.